Email :
Contact : (321) 445-1969

Immunotherapy in Hodgkin Lymphoma


Hodgkin's lymphoma is a lymphocyte cancer, with a 9,190 new cases per year in the U.S. It is sub-divided into two main categories: the Classical Hodgkin Lymphoma "CHL" and the Nodular lymphocyte predominant Hodgkin lymphoma "NLPHL". The main cause of Hodgkin lymphoma is not yet clear, but there are some risk factors like Epstein-Barr virus "EBV" infectious mononucleosis, HIV infection and genetic susceptibility. The aim of this review is to discuss the Immunotherapies available for Hodgkin lymphoma, as the treatment has developed over the past years decreasing its incidence and increasing the five year survival to 85.3%. Brentuximab Vedotin is the only immunotherapeutic drug which is FDA approved immunotherapy for the Hodgkin lymphoma, and there are several other drugs which are still under clinical trial.

Download Pdf